Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia
Yoshihiro Gocho, Jingjing Liu, Jianzhong Hu, Wentao Yang, Neekesh V. Dharia, Jingliao Zhang, Hao Shi, Guoqing Du, August John, Ting-Nien Lin, Jeremy P. Hunt, Xin Huang, Bensheng Ju, Lauren Rowland, Lei Shi, Dylan Maxwell, Brandon Smart, Kristine R. Crews, Wenjian Yang, Kohei Hagiwara, Yingchi Zhang, Kathryn G. Roberts, Hong Wang, Elias Jabbour, Wendy Stock, Bartholomew J. Eisfelder, Elisabeth Paietta, Scott Newman, Giovanni Roti, Mark R. Litzow, John Easton, Jinghui Zhang, Junmin Peng, Hongbo Chi, Stanley Pounds, Mary V. Relling, Hiroto Inaba, Xiaofan Zhu, Steven M. Kornblau, Ching‐Hon Pui, Marina Konopleva, David T. Teachey, Charles G. Mullighan, Kimberly Stegmaier, William E. Evans, Jiyang Yu, Jun J. Yang
Topics & Concepts
DasatinibVenetoclaxCancer researchLeukemiaJurkat cellsT cellEx vivoLymphoblastic LeukemiaMedicineBiologyMyeloid leukemiaIn vivoImmunologyChronic lymphocytic leukemiaImatinibGeneticsImmune systemAcute Lymphoblastic Leukemia researchChronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research